Zoll wins Japan's OK for next-gen monitor/defibrillator; Canada's regulators to make device data public;

@FierceMedDev: Covidien is acquiring Given Imaging, maker of the 'PillCam' oral endoscope, for $860M. More | Follow @FierceMedDev

@MarkHFierce: Zoll won Japanese approval for a next-gen monitor/defibrillator, marking its continued expansion in a giant HC mkt. Release | Follow @MarkHFierce

@MichaelGFierce: IT firm Cerner invests in Dx maker Claritas Genomics. Item | Follow @MichaelGFierce

@GalenMoore: Had breakfast yet? Here's a video of Pillcam's journey through the colon. Video | Follow @GalenMoore

> Zoll Medical won Japanese regulatory approval for its new X Series monitor/defibrillator. Item

> Foundation Medicine said its genomic profile for hematologic cancers worked well in a new trial, spotting genomic mutations that can't be seen with traditional methods. Item

> SafeStitch Medical, a maker of flexible instruments and robotics for minimally invasive surgery, has changed its name to TransEnterix, following its merger with the company. Item

> Chinese sleep therapy device company BMC Medical said it would fight back against archrival ReMed's patent infringement allegations filed in a German court. Item

> CareFusion ($CFN), perhaps best known for its infusion pumps and IV sets, is rolling out new software designed to help track unused IV medications to be returned to the hospital pharmacy for possible reuse. Item

> Canadian regulators plan to make medical device clinical data available to the public. Item

Biotech News

@FierceBiotech: 2013 American Society of Hematology annual meeting roundup: AbbVie, Gilead join Novartis in the center ring. Coverage | Follow @FierceBiotech

@JohnCFierce: Biogen forges a $200M preclinical Alzheimer's drug deal with Proteostasis. Story | Follow @JohnCFierce

@DamianFierce: "People who should have died 5 yrs ago are alive and well and in complete remission. It's a huge... shift." Story from Bloomberg | Follow @DamianFierce

@EmilyMFierce: A dried-up antibiotics pipeline has led two scientists to launch a crowdsourcing campaign for antibiotics research. Story | Follow @EmilyMFierce

> Novartis/Penn's customized T cell wows ASH with stellar leukemia data. More

> New era for hep C treatment begins with FDA OK for Gilead's sofosbuvir. Article

> Novartis is budgeting $6B a year for bolt-ons. Item

Pharma News

@FiercePharma: ICYMI Friday: The Adcock Ingram sale gets messier, with Bidvest upping stake to block $1.2B CFR Pharma buyout. More | Follow @FiercePharma

@EricPFierce: Former Actavis CEO Robert Wessman gets Iceland to invest $250M in his biosimilars aspirations. Friday's story | Follow @EricPFierce

@CarlyHFierce: Pentagon tasks Pfizer with radically rethinking vaccine development. Story from FierceVaccines | Follow @CarlyHFierce

> Auxilium's Xiaflex is approved to treat painful curved penis condition. Story

> The feds zero in on United Therapeutics' marketing practices. Report

> Power struggle at Novartis? Not at all, new chairman says. More

> J&J, Roche, Novartis tout key cancer-drug data at ASH. Report

CRO News

> Sarah Cannon buys a clinical trial outfit to expand its cancer reach. Story

> Fast-growing Agilux doubles its preclinical space. News

> Venn snags an Irish CRO in its global buyout push. Report

> Charles River recruits Sloan-Kettering CEO to bolster its science. More

> Pfizer's unlocked trial data could be a boon to CROs. Article

> Sluggish Parexel could be poised for a long-term turnaround. Item

Biotech IT News

> Pfizer is opening up clinical trial data to researchers, patients starting in 2014. Report

> Wanted: 1,000 citizen scientists to crowdsource antibiotics research. Story

> Report tips analytics to get biopharma out of its productivity slump. News

> U.K. sets up $16M competition to find genome data analysis tools. Article

> Text mining 88,000 papers gives Pfizer a drug safety database. More

> Machine learning improves accuracy of flu forecasts. Item

Suggested Articles

Johnson & Johnson Vision announced that the worldwide president of its surgical business, Tom Frinzi, plans to retire at the end of this year.

Philips looked back on 15 years of data from one of its telehealth-equipped intensive care units, where centralizing operations reduced mortality.

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.